Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00548405 (ClinicalTrials.gov)	October 2007	22/10/2007	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two	A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy	Multiple Sclerosis, Relapsing-Remitting	Biological: Alemtuzumab 12 mg;Biological: Alemtuzumab 24 mg;Biological: Interferon beta -1a	Genzyme, a Sanofi Company	Bayer	Completed	18 Years	55 Years	All	840	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom
2	NCT00050778 (ClinicalTrials.gov)	December 2002	19/12/2002	A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis	A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: Interferon beta -1a;Biological: Alemtuzumab 12 mg;Biological: Alemtuzumab 24 mg	Genzyme, a Sanofi Company	Bayer	Completed	18 Years	50 Years	All	334	Phase 2	United States;Croatia;Poland;Russian Federation;United Kingdom